Greg Miller has spent the last two decades enabling therapeutics companies to reach their potential through financings and establishing strategic partnerships.

Greg was most recently the CEO of Transition Bio, where he secured the company’s series A and helped to expand the scientific leadership team to enable condensate drug discovery. Prior to that, he held senior business development roles at Atalanta Therapeutics, Visterra Inc. (acquired) and Concert Pharmaceuticals (IPO), where he formed numerous collaborations to accelerate novel drug discovery platforms. Greg began his career at Genzyme Corporation.

Greg holds an MBA and MPH from Boston University.